Clinical trial
An Open Label Dose Escalation Study Of E7080
NCT00121719 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00121719 |
|---|---|
| Title | An Open Label Dose Escalation Study Of E7080 |
| Official title | An Open Label Phase I Dose Escalation Study Of E7080 |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumor or Lymphoma |
| Intervention type | Drug |
| Interventions | Lenvatinib |
| Enrollment | 82 |
| Start date | Jul 1, 2005 |
| Primary completion | Jun 19, 2009 |
| Completion | Mar 1, 2019 |
| First posted | Jul 21, 2005 |
| Last update posted | Jun 22, 2023 |
| Countries | Netherlands, United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: